ArticleAnnals of hematology2026

Real-world effectiveness of zanubrutinib plus salvage chemotherapy in relapsed or refractory double-expressor DLBCL.

Jinbo Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.